Projects per year
Fingerprint
Dive into the research topics where Iris Dirven is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 1 Similar Profiles
Collaborations and top research areas from the last five years
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
Projects
- 1 Finished
-
AIIFUND147: Visiting Research Agreement Melanoma Therapies
Neyns, B. (Administrative Promotor) & Dirven, I. (PI (Promotor, Principal Investigator))
1/05/25 → 30/06/25
Project: Fundamental
-
Combined immunotherapy with nivolumab and ipilimumab with and without sequential or concomitant stereotactic radiotherapy in patients with melanoma brain metastasis: An international retrospective study
Mandalà, M., Amaral, T., Rutkowski, P., Sergi, M., Rasch, M.-L., Benannoune, N., Serra, P., Vitale, M., Giannarelli, D., Arance, A., Couselo, E., Neyns, B., Dirven, I., Tucci, M., Guida, M., Spagnolo, F., Rossi, E., Queirolo, P., Quaglino, P. & Depenni, R. & 11 others, , 25 Jul 2025, In: European Journal of Cancer. 225, p. 1-7 7 p., 115567.Research output: Contribution to journal › Article › peer-review
Open AccessFile1 Citation (Scopus) -
Infliximab is a safe and effective treatment in steroid-refractory immune-related hepatitis
Oliva, K. N., Arnold, L., Heinzerling, L., Meier, F., Hartmann, S., Meier, K., Huynh, J., Schlaak, M., Gesierich, A., Dirven, I., Trojan, J., Kleemann, J. & Schilling, B., 23 Sept 2025, In: Journal for ImmunoTherapy of Cancer. 13, 9, 6 p., e013038.Research output: Contribution to journal › Article › peer-review
Open AccessFile -
Levenskwaliteit en neurocognitief functioneren bij recurrent glioblastoom na respons op intracraniale immunotherapie
Vanlaer, N., Testaferrata, C., Dierck, B., Dirven, I., Cleo, B., Lescrauwaet, L., Duerinck, J., Neyns, B. & Rogiers, A., 5 Dec 2025.Research output: Unpublished contribution to conference › Poster
-
Psychosociaal en cognitief functioneren en levenskwaliteit bij overlevenden van gevorderde kanker behandeld met immunotherapie
Vanlaer, N., Dirven, I., Decabooter, L., Testaferrata, C., Neyns, B. & Rogiers, A., 5 Dec 2025.Research output: Unpublished contribution to conference › Poster
-
A phase 2 clinical trial of regorafenib in patients with advanced pretreated melanoma (RegoMel)
Dirven, I., Vounckx, M., Kessels, J. I. E., Vanlaer, N., von Kemp, B., Fasolino, G. & Neyns, B., 1 Jun 2024, In: Journal of Clinical Oncology. 42, 16, 9518.Research output: Contribution to journal › Meeting abstract (Journal)
Open Access
Prizes
Activities
-
Management of patients with melanoma central nervous system metastases
Dirven, I. (Speaker)
18 Oct 2025Activity: Talk or presentation › Talk or presentation at a conference
-
2025 ASCO Annual Meeting
Aspeslagh, S. (Participant), Cleo, B. (Chair) & Dirven, I. (Chair)
30 May 2025 → 3 Jun 2025Activity: Participating in or organising an event › Participation in conference
-
A phase I clinical trial on combined (neo-)adjuvant intravenous plus intracranial administration of ipilimumab and nivolumab in recurrent glioblastoma (NEO-GLITIPNI).
Dirven, I. (Speaker)
31 May 2025Activity: Talk or presentation › Talk or presentation at a conference
-
Melanoma treatment Anno 2024
Dirven, I. (Speaker)
9 Mar 2024Activity: Talk or presentation › Talk at a public lecture/debate
-
A phase 2 clinical trial of regorafenib in patients with advanced pretreated melanoma (RegoMel).
Dirven, I. (Speaker)
1 Jun 2024Activity: Talk or presentation › Talk or presentation at a conference